Cargando…

Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines

Introduction. Risankizumab is a humanized monoclonal antibody of the immunoglobulin G1 (IgG1) type that binds selectively, and with high affinity, to the p19 subunit of interleukin-23 (IL-23), resulting in the inhibition of inflammation and clinical symptoms associated with psoriasis. Its introducti...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruiz-Villaverde, Ricardo, Rodriguez-Fernandez-Freire, Lourdes, Pérez-Gil, Amalia, Font-Ugalde, Pilar, Galán-Gutiérrez, Manuel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697008/
https://www.ncbi.nlm.nih.gov/pubmed/36431015
http://dx.doi.org/10.3390/life12111883
_version_ 1784838452322238464
author Ruiz-Villaverde, Ricardo
Rodriguez-Fernandez-Freire, Lourdes
Pérez-Gil, Amalia
Font-Ugalde, Pilar
Galán-Gutiérrez, Manuel
author_facet Ruiz-Villaverde, Ricardo
Rodriguez-Fernandez-Freire, Lourdes
Pérez-Gil, Amalia
Font-Ugalde, Pilar
Galán-Gutiérrez, Manuel
author_sort Ruiz-Villaverde, Ricardo
collection PubMed
description Introduction. Risankizumab is a humanized monoclonal antibody of the immunoglobulin G1 (IgG1) type that binds selectively, and with high affinity, to the p19 subunit of interleukin-23 (IL-23), resulting in the inhibition of inflammation and clinical symptoms associated with psoriasis. Its introduction has managed to increase the levels of efficacy and safety (improving upon those previously presented by the anti-IL-23 class). Material and methods. Retrospective analysis of a multicenter, observational study of real clinical practice, including patients with moderate-to-severe plaque psoriasis in treatment with risankizumab. This cross-sectional analysis includes information on patients from May 2020 to June 2022. A total of six tertiary hospitals in Andalusia (Spain) participated in this study. Analyses were performed “as observed” using GraphPad Prism version 8.3.0 for Windows. Results. Regarding the percentage of patients who reached PASI 90 or PASI 100 at week 52, 92.5% achieved the therapeutic goal of PASI 90, and 78.5% reached PASI 100. When analyzing the results by absolute PASI, we found that 78.5% (n = 33) obtained PASI 0, 85.7% (n = 36) obtained PASI ≤ 1, and all patients achieved PASI ≤ 3 (disease control). Discussion. Risankizumab has shown promising results in the control of psoriasis in the long-term, with a high percentage of patients (>80%) maintaining PASI 90 and PASI 100 up to 52 weeks of treatment. No abnormal safety findings have been reported, and risankizumab appears to be a solid treatment in the different scenarios analyzed.
format Online
Article
Text
id pubmed-9697008
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96970082022-11-26 Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines Ruiz-Villaverde, Ricardo Rodriguez-Fernandez-Freire, Lourdes Pérez-Gil, Amalia Font-Ugalde, Pilar Galán-Gutiérrez, Manuel Life (Basel) Article Introduction. Risankizumab is a humanized monoclonal antibody of the immunoglobulin G1 (IgG1) type that binds selectively, and with high affinity, to the p19 subunit of interleukin-23 (IL-23), resulting in the inhibition of inflammation and clinical symptoms associated with psoriasis. Its introduction has managed to increase the levels of efficacy and safety (improving upon those previously presented by the anti-IL-23 class). Material and methods. Retrospective analysis of a multicenter, observational study of real clinical practice, including patients with moderate-to-severe plaque psoriasis in treatment with risankizumab. This cross-sectional analysis includes information on patients from May 2020 to June 2022. A total of six tertiary hospitals in Andalusia (Spain) participated in this study. Analyses were performed “as observed” using GraphPad Prism version 8.3.0 for Windows. Results. Regarding the percentage of patients who reached PASI 90 or PASI 100 at week 52, 92.5% achieved the therapeutic goal of PASI 90, and 78.5% reached PASI 100. When analyzing the results by absolute PASI, we found that 78.5% (n = 33) obtained PASI 0, 85.7% (n = 36) obtained PASI ≤ 1, and all patients achieved PASI ≤ 3 (disease control). Discussion. Risankizumab has shown promising results in the control of psoriasis in the long-term, with a high percentage of patients (>80%) maintaining PASI 90 and PASI 100 up to 52 weeks of treatment. No abnormal safety findings have been reported, and risankizumab appears to be a solid treatment in the different scenarios analyzed. MDPI 2022-11-14 /pmc/articles/PMC9697008/ /pubmed/36431015 http://dx.doi.org/10.3390/life12111883 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ruiz-Villaverde, Ricardo
Rodriguez-Fernandez-Freire, Lourdes
Pérez-Gil, Amalia
Font-Ugalde, Pilar
Galán-Gutiérrez, Manuel
Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines
title Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines
title_full Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines
title_fullStr Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines
title_full_unstemmed Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines
title_short Risankizumab: Efficacy, Safety, and Survival in the Mid-Term (52 Weeks) in Real Clinical Practice in Andalusia, Spain, According to the Therapeutic Goals of the Spanish Psoriatic Guidelines
title_sort risankizumab: efficacy, safety, and survival in the mid-term (52 weeks) in real clinical practice in andalusia, spain, according to the therapeutic goals of the spanish psoriatic guidelines
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697008/
https://www.ncbi.nlm.nih.gov/pubmed/36431015
http://dx.doi.org/10.3390/life12111883
work_keys_str_mv AT ruizvillaverdericardo risankizumabefficacysafetyandsurvivalinthemidterm52weeksinrealclinicalpracticeinandalusiaspainaccordingtothetherapeuticgoalsofthespanishpsoriaticguidelines
AT rodriguezfernandezfreirelourdes risankizumabefficacysafetyandsurvivalinthemidterm52weeksinrealclinicalpracticeinandalusiaspainaccordingtothetherapeuticgoalsofthespanishpsoriaticguidelines
AT perezgilamalia risankizumabefficacysafetyandsurvivalinthemidterm52weeksinrealclinicalpracticeinandalusiaspainaccordingtothetherapeuticgoalsofthespanishpsoriaticguidelines
AT fontugaldepilar risankizumabefficacysafetyandsurvivalinthemidterm52weeksinrealclinicalpracticeinandalusiaspainaccordingtothetherapeuticgoalsofthespanishpsoriaticguidelines
AT galangutierrezmanuel risankizumabefficacysafetyandsurvivalinthemidterm52weeksinrealclinicalpracticeinandalusiaspainaccordingtothetherapeuticgoalsofthespanishpsoriaticguidelines